S&P 500   4,263.89 (+0.81%)
DOW   33,131.92 (+0.39%)
QQQ   360.35 (+1.53%)
AAPL   174.10 (+0.99%)
MSFT   319.79 (+2.04%)
META   306.58 (+1.87%)
GOOGL   135.53 (+2.34%)
AMZN   127.14 (+1.94%)
TSLA   261.07 (+5.90%)
NVDA   439.99 (+1.11%)
NIO   8.80 (+2.21%)
BABA   84.03 (-0.60%)
AMD   104.26 (+4.18%)
T   14.61 (-1.15%)
F   12.01 (-0.50%)
MU   68.26 (+0.63%)
CGC   0.77 (+12.41%)
GE   109.03 (+1.18%)
DIS   79.31 (-0.29%)
AMC   8.34 (+6.24%)
PFE   33.28 (-1.83%)
PYPL   58.59 (+2.25%)
NFLX   376.45 (-0.08%)
S&P 500   4,263.89 (+0.81%)
DOW   33,131.92 (+0.39%)
QQQ   360.35 (+1.53%)
AAPL   174.10 (+0.99%)
MSFT   319.79 (+2.04%)
META   306.58 (+1.87%)
GOOGL   135.53 (+2.34%)
AMZN   127.14 (+1.94%)
TSLA   261.07 (+5.90%)
NVDA   439.99 (+1.11%)
NIO   8.80 (+2.21%)
BABA   84.03 (-0.60%)
AMD   104.26 (+4.18%)
T   14.61 (-1.15%)
F   12.01 (-0.50%)
MU   68.26 (+0.63%)
CGC   0.77 (+12.41%)
GE   109.03 (+1.18%)
DIS   79.31 (-0.29%)
AMC   8.34 (+6.24%)
PFE   33.28 (-1.83%)
PYPL   58.59 (+2.25%)
NFLX   376.45 (-0.08%)
S&P 500   4,263.89 (+0.81%)
DOW   33,131.92 (+0.39%)
QQQ   360.35 (+1.53%)
AAPL   174.10 (+0.99%)
MSFT   319.79 (+2.04%)
META   306.58 (+1.87%)
GOOGL   135.53 (+2.34%)
AMZN   127.14 (+1.94%)
TSLA   261.07 (+5.90%)
NVDA   439.99 (+1.11%)
NIO   8.80 (+2.21%)
BABA   84.03 (-0.60%)
AMD   104.26 (+4.18%)
T   14.61 (-1.15%)
F   12.01 (-0.50%)
MU   68.26 (+0.63%)
CGC   0.77 (+12.41%)
GE   109.03 (+1.18%)
DIS   79.31 (-0.29%)
AMC   8.34 (+6.24%)
PFE   33.28 (-1.83%)
PYPL   58.59 (+2.25%)
NFLX   376.45 (-0.08%)
S&P 500   4,263.89 (+0.81%)
DOW   33,131.92 (+0.39%)
QQQ   360.35 (+1.53%)
AAPL   174.10 (+0.99%)
MSFT   319.79 (+2.04%)
META   306.58 (+1.87%)
GOOGL   135.53 (+2.34%)
AMZN   127.14 (+1.94%)
TSLA   261.07 (+5.90%)
NVDA   439.99 (+1.11%)
NIO   8.80 (+2.21%)
BABA   84.03 (-0.60%)
AMD   104.26 (+4.18%)
T   14.61 (-1.15%)
F   12.01 (-0.50%)
MU   68.26 (+0.63%)
CGC   0.77 (+12.41%)
GE   109.03 (+1.18%)
DIS   79.31 (-0.29%)
AMC   8.34 (+6.24%)
PFE   33.28 (-1.83%)
PYPL   58.59 (+2.25%)
NFLX   376.45 (-0.08%)
NASDAQ:CMMB

Chemomab Therapeutics (CMMB) News Today

$0.86
-0.04 (-3.89%)
(As of 03:35 PM ET)
Compare
Today's Range
$0.85
▼
$0.89
50-Day Range
$0.88
▼
$1.34
52-Week Range
$0.83
▼
$5.35
Volume
19,309 shs
Average Volume
353,745 shs
Market Capitalization
$9.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media
SourceHeadline
finance.yahoo.com logoChemomab Therapeutics to Present Its CM-101 Clinical Program in Primary Sclerosing Cholangitis at 2023 Roth MKM Healthcare Opportunities Conference
finance.yahoo.com - September 28 at 8:29 AM
finance.yahoo.com logoChemomab Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
finance.yahoo.com - August 29 at 9:20 AM
finanznachrichten.de logoChemomab Therapeutics, Ltd.: Chemomab Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Corporate Update
finanznachrichten.de - August 14 at 10:02 AM
finance.yahoo.com logoChemomab Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Corporate Update
finance.yahoo.com - August 14 at 10:02 AM
msn.com logoChemomab Therapeutics Ltd - ADR (CMMB) Price Target Increased by 70.45% to 25.50
msn.com - July 6 at 3:17 PM
finance.yahoo.com logoChemomab Therapeutics Announces Publication in JCI Insight Demonstrating Key Role of CCL24 in Primary Sclerosing Cholangitis
finance.yahoo.com - June 28 at 10:15 AM
finance.yahoo.com logoChemomab Therapeutics Presents Data Reinforcing the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2023
finance.yahoo.com - June 26 at 8:03 AM
msn.com logoWhat's Going On With Chemomab Therapeutics Stock Today
msn.com - June 21 at 10:59 AM
finance.yahoo.com logoChemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023
finance.yahoo.com - June 21 at 10:59 AM
msn.com logoOppenheimer Downgrades Chemomab Therapeutics Ltd - ADR (CMMB)
msn.com - June 7 at 9:41 AM
markets.businessinsider.com logoHemomab Therapeutics Reappoints Adi Mor As CEO; Sigal Fattal Reassumes Role Of CFO
markets.businessinsider.com - June 5 at 10:27 AM
msn.com logoChemomab Therapeutics announces key management changes
msn.com - June 5 at 10:27 AM
finance.yahoo.com logoChemomab Therapeutics Announces Executive Leadership Changes and Provides a Corporate Update
finance.yahoo.com - June 5 at 10:27 AM
finance.yahoo.com logoPatient Data Presented at 2023 EULAR Congress Highlights How Serum CCL24 Levels Can Predict Vascular and Fibrotic Complications of Systemic Sclerosis
finance.yahoo.com - June 2 at 1:22 PM
finance.yahoo.com logoChemomab Therapeutics to Participate in Upcoming Scientific Conferences
finance.yahoo.com - May 24 at 8:02 AM
finance.yahoo.com logoChemomab Therapeutics Ltd. (NASDAQ:CMMB) Q1 2023 Earnings Call Transcript
finance.yahoo.com - May 16 at 3:05 PM
finanznachrichten.de logoChemomab Therapeutics, Ltd.: Chemomab Therapeutics Announces First Quarter 2023 Financial Results and Provides a Corporate Update
finanznachrichten.de - May 11 at 9:55 AM
finance.yahoo.com logoChemomab Therapeutics Announces First Quarter 2023 Financial Results and Provides a Corporate Update
finance.yahoo.com - May 11 at 9:55 AM
finance.yahoo.com logoChemomab Therapeutics to Present at 2023 Aegis Virtual Conference
finance.yahoo.com - April 26 at 9:32 AM
msn.com logoOppenheimer Maintains Chemomab Therapeutics (CMMB) Outperform Recommendation
msn.com - April 19 at 1:52 AM
finance.yahoo.com logoChemomab Therapeutics to Discuss First Quarter 2023 Financial Results and Provide a Corporate Update
finance.yahoo.com - April 12 at 8:29 AM
benzinga.com logoChemomab Therapeutics Stock (NASDAQ:CMMB), Guidance and Forecast
benzinga.com - March 31 at 6:39 PM
msn.com logoA Preview Of Chemomab Therapeutics's Earnings
msn.com - March 30 at 3:10 PM
finance.yahoo.com logoChemomab Therapeutics to Provide a Corporate Update on April 17, 2023
finance.yahoo.com - March 29 at 8:38 AM
finance.yahoo.com logoChemomab Therapeutics to Discuss Fourth Quarter and Full-Year 2022 Financial Results and Provide a Business Update
finance.yahoo.com - March 17 at 9:04 AM
finance.yahoo.com logoChemomab to Present at the Oppenheimer 33rd Annual Healthcare Conference
finance.yahoo.com - March 6 at 9:46 AM
marketwatch.com logoChemomab Therapeutics Shares Fall 16%, Hitting 52-Week Low
marketwatch.com - February 25 at 7:40 AM
morningstar.com logoChemomab Therapeutics stock soars after FDA clears IND for SSc treatment
morningstar.com - February 23 at 8:20 PM
finance.yahoo.com logoIs Chemomab Therapeutics (NASDAQ:CMMB) In A Good Position To Invest In Growth?
finance.yahoo.com - February 23 at 10:18 AM
marketwatch.com logoChemomab Therapeutics Climbs After FDA Clears Application for SSc Treatment
marketwatch.com - February 21 at 5:29 PM
msn.com logoWhy Chemomab Therapeutics Shares Are Trading Higher Today
msn.com - February 21 at 5:29 PM
yahoo.com logoFDA Gives Green Signal To Chemomab Therapeutics' Rare Disease Study
yahoo.com - February 21 at 5:29 PM
markets.businessinsider.com logoChemomab (CMMB) Stock Gains 30% on FDA Clearance
markets.businessinsider.com - February 21 at 12:29 PM
finance.yahoo.com logoChemomab Announces FDA Clearance of Investigational New Drug Application for Phase 2 Clinical Trial of CM-101 in Patients with Systemic Sclerosis
finance.yahoo.com - February 21 at 7:27 AM
wsj.com logoChemomab Therapeutics Ltd. ADR
wsj.com - January 18 at 5:19 PM
nasdaq.com logoChemomab (CMMB) Mid-Stage Study for NASH Meets Primary Goal
nasdaq.com - January 4 at 3:02 PM
nasdaq.com logoChemomab Jumps 35% After Reporting NASH Trial Data
nasdaq.com - January 3 at 1:05 PM
marketwatch.com logoChemomab Shares Rally Premarket on Positive CM-101 Study >CMMB
marketwatch.com - January 3 at 8:04 AM
finance.yahoo.com logoChemomab Reports Top-Line Results from CM-101 Phase 2a Liver Fibrosis Biomarker Trial in NASH Patients
finance.yahoo.com - January 3 at 8:04 AM
finance.yahoo.com logoChemomab Reports Independent Drug Monitoring Committee Safety Review of CM-101 Phase 2 Trial in Primary Sclerosing Cholangitis
finance.yahoo.com - December 21 at 8:53 AM
benzinga.com logoChief Scientific Officer At This Health Care Company Sells $1.21M of Stock
benzinga.com - November 18 at 11:14 AM
benzinga.com logoChemomab Announces Appointment of Matthew Frankel, MD, MBA as Chief Medical Officer
benzinga.com - November 14 at 10:57 AM
msn.com logoEarnings Preview: Chemomab Therapeutics
msn.com - November 10 at 4:53 PM
finance.yahoo.com logoChemomab Presents Clinical Data from Investigator-Initiated Study Showing CM-101 Reduced Inflammatory and Fibrogenesis-Related Biomarkers in Patients with Severe Lung Injury Derived from Covid-19
finance.yahoo.com - November 9 at 10:38 AM
finance.yahoo.com logoChemomab Therapeutics to Report Third Quarter 2022 Financial Results and Provide a Business Update
finance.yahoo.com - November 1 at 11:49 AM
finance.yahoo.com logoChemomab Therapeutics to Present at Upcoming Scientific Conferences
finance.yahoo.com - October 28 at 9:43 AM
finance.yahoo.com logoHere's Why We're Not Too Worried About Chemomab Therapeutics' (NASDAQ:CMMB) Cash Burn Situation
finance.yahoo.com - September 16 at 8:46 AM
seekingalpha.com logoChemomab Therapeutics Ltd. (CMMB) CEO Dale Pfost on Q2 2022 Results - Earnings Call Transcript
seekingalpha.com - August 12 at 5:12 PM
msn.com logoChemomab Therapeutics: Q2 Earnings Insights
msn.com - August 12 at 7:04 AM
finance.yahoo.com logoChemomab Adds Highly Experienced Executives Further Strengthening Its R&D and Clinical Capabilities
finance.yahoo.com - August 12 at 7:04 AM
Get Chemomab Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CMMB and its competitors with MarketBeat's FREE daily newsletter.



CMMB Media Mentions By Week

CMMB Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CMMB
News Sentiment
▼
1.54

0.48
▲
Average
Medical
News Sentiment

CMMB News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CMMB Articles
This Week
▼
1

0
▲
CMMB Articles
Average Week

Get Chemomab Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CMMB and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:CMMB) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -